Rho

The Neuroscience of Connection Neurology and psychiatry aren't just about treating diseases-they're about understanding what makes us human. At Rho, we know real progress happens when we bring patients into the conversation. On April 7, at #CMOSummit360, Peter Schmidt, Rho's President & CSO, will join #BioVie and other leaders on the panel, "How to Better Partner with Patient Organizations." Because the best treatments don't come from science alone-they come from listening to the people who need them.

How is Huntington’s disease treatment evolving? At #AAN2025, Dr. Andrew Feigin, our Chief Medical Officer, will be tackling that very question. Join him on April 8 at 9:15AM, as he takes the plenary stage to discuss the Phase 3 PROOF-HD trial and what its findings on pritopidine could mean for the future of Huntington’s disease treatment. Because progress happens when science and expertise come together.

An SDSP isn't just another document; it's a roadmap for submission success. A well thought out plan keeps things on track and minimizes surprises, making life easier for everyone involved. Thank you, Hilary Wall, for shedding light on how to get it done from the start!

Pi is Irrational. Our Science Isn't. Today's the day to celebrate the never-ending π but at Rho, we prefer our numbers a little more...conclusive. But great research isn't just about the data-it's about bringing everything together to build scientifically rigorous, cohesive clinical trials that move drug development forward. So stay tuned and in the meantime, grab yourself a slice of pie-because some things are worth geeking over.

It's more than just a peanut problem. Whether it's a child navigating a school lunch, an adult scanning ingredient labels, or a researcher pushing for better solutions, food allergies affect real lives every day. That's why the insights from the OUtMATCH study matter and why we are so proud to have played a role in advancing this critical research. Thank you, Nicole Rogers, for highlighting this research from #NIAID, reinforcing how good science is moving the needle toward better treatments. More than just a peanut problem. Progress is happening. Let's keep it going.

Major Breakthrough in Food Allergy Treatment-Is this the Future? Dr. Robert Wood of Johns Hopkins dropped game changing news at #AAAAI. In a late breaking session, new Phase 2 and Phase 3 OUtMATCH study data reinforced what many had hoped- the case for Xolair (omalizumab) as a powerful option for protecting against multiple food allergies. But here's the real breakthrough: in the first ever head-to-head trial against multi allergen oral immunotherapy (OIT), the OUtMATCH study confirmed Xolair outperformed OIT, showing greater effectiveness with fewer severe reactions. Genentech's latest press release dives deeper into these findings. What comes next? At Rho, we know that getting from promising data to real world change requires operational precision, regulatory foresight, and an unwavering commitment to data integrity. We are proud of our role in this journey and the work we do to help bring meaningful change. The future of biologics in allergy treatment is taking shape-is this the shift that redefines standard care? What do you think?

San Diego looks good on our team! If you're at #AAAAI, swing by BOOTH 1425 and connect with our Rho experts. Their passion and knowledge of the food allergy space will spark some meaningful and interesting conversations!

Partnership means more than just showing up-it means driving conversations that matter. That's why we're proud to have Hannah and Sophie represent Rho at #COGUK next week. If you're planning to attend, don't miss the opportunity to connect and dive into some great discussions.

The story isn’t over. Last week we shared why the study behind FDA's approval of omalizumab for food allergy treatment is such a milestone. But breakthroughs don't stop at approval. On Sunday, March 2, at American Academy of Allergy, Asthma & Immunology #AAAAI, experts will take the stage for a plenary session on the next phase of this breakthrough food allergy study. This session is expected to be a major draw—stay tuned as we continue supporting critical advancements in clinical research.

Heading to #SCRS? Be sure to connect with Michael and Maris while you're there. They'll be deep in conversations about site engagement and collaboration and look forward to strengthening connections with sites and site networks across Europe. If you're in Lisbon, don't miss the chance to be part of the conversation.